However, some oncogenic drivers, such as sensitizing epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangements, have shown less benefit from immunotherapy for advanced NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.